Efficacy
emesis
The proportion of patients with sustained complete response during CCRT was 20.4% (95% CI, 10.7%-34.8%) for the group receiving weekly fosaprepitant compared with 12.5% (95% CI, 5.1%-25.9%) for those receiving fosaprepitant every 3 weeks. There was no statistically significant difference in cumulative risk of emesis or rescue therapy between groups (subhazard ratio, 0.66 [95% CI, 0.43-1.02]; 